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tion-specific inhibitors. Patient strati-
fication and matching the drug to the 
mutation will be an important strategy to 
ensure successful treatment of malig-
nancies such as NSCLC. Furthermore, 
most patients on prolonged gefitinib 
and erlotinib treatment develop sec-
ondary mutations in the EGFR kinase 
domain that block drug binding, lead-
ing to clinical resistance and therapy 
failure (Kobayashi et al., 2005; Kwak et 
al., 2005; Pao et al., 2005). The ability 
to synthesize drugs that inhibit through 
different binding modes will be cru-
cial if we are to tackle this increasingly 
important clinical problem. Finally, the 
information learned for the EGFR will 
have important ramifications for other 
kinases, such as BCR-ABL, which also 
binds to drugs in either the active and 
inactive conformations (Liu and Gray, 
2006; Schindler et al., 2000).
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In this issue of Cancer Cell, Guerra and colleagues provide important new insights regarding the 
ability of specific pancreatic cell types to generate invasive pancreatic cancer. First, they demon-
strate that classical pancreatic “ductal” neoplasia can be induced by activation of oncogenic Kras 
in nonductal exocrine cells. Second, they show that, while Kras activation in immature acinar and 
centroacinar cells is readily able to induce ductal neoplasia, Kras-mediated tumorigenesis in mature 
exocrine pancreas requires the induction of chronic epithelial injury. The results shed new light on 
the “cell of origin” of pancreatic ductal cancer and demonstrate that chronic pancreatitis provides a 
permissive environment for Kras-induced pancreatic neoplasia.Among the many problems of cancer 
research, “cell-of-origin” questions 
may occasionally be viewed as trivial 
or semantic. Yet tumors are not born 
equal: for example, pancreatic duc-
tal adenocarcinomas (PDACs) nearly 
always arise from precursors that sus-
tain activating KRAS mutations, while such mutations are almost never seen in 
less common pancreatic cancers such 
as islet cell carcinomas. Some of these 
differences may reflect the internal wir-
ing of the initiating cell types, such that 
KRAS activation favors transformation 
in one cell but not another. Decipher-
ing these interactions between epi-Cancer Cell genetic determinants of cell identity 
and genetic changes leading to tumor 
formation might identify new targets 
for cancer treatment and prevention. In 
this issue of Cancer Cell, Guerra et al. 
(2007) make an important and surpris-
ing advance in clarifying the adult cell 
of origin for PDAC.11, March 2007 ©2007 Elsevier Inc. 211
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Previewsfigure 1. Potential cellular sources of Pancreatic cancer
The study of Guerra et al. (2007) indicates that KrasG12V mutations arising in acinar (top) or cen-
troacinar (bottom) cells of the adult pancreas can give rise to pancreatic intraepithelial neoplasia 
(PanIN) lesions and invasive pancreatic ductal adenocarcinoma (PDAC). In the mature pancreas, 
the vast majority of both cell types appear to tolerate expression of activated Kras without effect. 
Chronic injury, however, dramatically sensitizes the adult pancreas to KrasG12V-driven dysplasia, 
possibly by evoking the formation of metaplastic tubular complexes that are uniquely sensitive to 
the effects of the oncogene. Such complexes might arise from the transdifferentiation of mature 
acinar cells, from the expansion of a pre-existing centroacinar cell population, or both.What are the possible cellular 
compartments in which PDAC-
producing KRAS mutations might 
occur? PDAC is often assumed to 
arise from preexisting duct cells, 
based on the fact that the two 
known pancreatic cancer precur-
sor lesions—pancreatic intraepi-
thelial neoplasia (PanIN) and intra-
ductal papillary mucinous neoplasia 
(IPMN)—both exhibit features of 
ductal differentiation. This hypoth-
esis has been surprisingly difficult 
to prove: direct targeting of onco-
genic Kras to mature ductal cells, 
using the Cytokeratin 19 promoter, 
fails to induce neoplasia (Brembeck 
et al., 2003). In contrast, similar 
transgenic studies reveal that aci-
nar cells, which comprise the most 
abundant cell type in mature pan-
creas, are susceptible to transfor-
mation by a variety of oncogenes 
(including Kras) and give rise to 
tumors that often contain ductal ele-
ments (Hruban et al., 2006). In addi-
tion to acini and ducts, of course, 
the pancreas is also comprised of 
endocrine islets, as well as several 
less common cell types, including 
centroacinar cells and clear (“Helle 
Zelle”) cells. Centroacinar cells have 
recently been implicated as the 
apparent source of ductal tumors 
induced by pancreas-specific Pten 212 Cancer Cell 11, March 2007 ©2007 Edeletion (Stanger et al., 2005), and 
chemical carcinogenesis studies 
in rat and hamster have suggested 
that hyperplastic lesions leading 
to ductal tumors may be initiated 
among a variety of nonductal cell 
types (Bockman et al., 2003; Pour 
et al., 2003). Although all of these 
studies have provided fascinating 
insights into cellular plasticity in the 
setting of neoplastic transformation, 
it has been difficult to reconcile their 
conclusions, or extrapolate to the 
human form of the disease. Chemi-
cal carcinogenesis can, in princi-
ple, affect multiple pancreatic cell 
types, making it almost impossible 
to establish a lineage relationship 
between normal cells, precancer-
ous lesions, and invasive tumors. 
Transgenic constructs are likely to 
produce nonphysiological levels of 
oncogene expression, and use of 
heterologous cell type-specific pro-
moters essentially limits the abil-
ity of a tumor to change its cellular 
phenotype. Perhaps for this reason, 
most of these models have failed to 
recapitulate the PanIN/PDAC pro-
gression seen in humans (Hruban et 
al., 2006).
A recent breakthrough in PDAC 
modeling came with the develop-
ment of conditionally activatable 
Kras alleles in the mouse (Aguirre lsevier Inc.et al., 2003; Hingorani et al., 2003). 
These alleles are silent in the major-
ity of cells, yet can be heritably acti-
vated by Cre-loxP recombination, 
mimicking the somatic KRAS point 
mutations that initiate PDAC for-
mation in human pancreas. When 
this system is used to activate Kras 
throughout the developing pancreas, 
adult mice develop a PanIN/PDAC 
progression that is almost indistin-
guishable from its human counter-
part (Hruban et al., 2006). Because 
the initial applications of this system 
relied on pan-pancreatic Kras acti-
vation, they could not address the 
cell-of-origin question, and it is into 
this breach that Guerra et al. (2007) 
now step. These authors have 
developed a tetracycline-regulated 
system in which Cre recombinase is 
conditionally expressed under con-
trol of the acinar-specific Elastase 
promoter. Using this system, they 
demonstrate the formation of clas-
sic PanINs, and eventual invasive 
PDAC, following Cre-mediated acti-
vation of a conditional KrasG12V allele 
in nonductal exocrine cells.
Unfortunately, this system does 
not fully resolve the cell-of-origin 
question for PDAC, as the authors 
observe Cre-loxP recombination 
in centroacinar as well as acinar 
cells. Centroacinar cells lie at the 
junction between acinar cells and 
adjacent ductal epithelium, and as 
noted above have previously been 
proposed as a potential source 
for ductal neoplasia (Stanger et 
al., 2005). In addition, centroaci-
nar cells have been suggested to 
represent a stem- or progenitor-
like population for the adult pan-
creas, particularly following injury. 
Although the resting pancreas is a 
relatively quiescent organ, with little 
evidence for dedicated stem cells, 
experimental injury elicits the tran-
sient appearance and proliferation 
of progenitor-like cells, variously 
termed “tubular complexes” or “aci-
nar-ductal metaplasia” (Bockman, 
1997). The origin of these cells is 
no better understood than that of 
PDAC (indeed, experimental PDAC 
models are often associated with 
similar metaplastic structures): do 
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acinar cells, or from the expansion 
of centroacinar or duct cells?
This question bears on another 
provocative finding of Guerra et al. 
(2007), that experimental pancreati-
tis dramatically sensitizes mice to 
KrasG12V-driven PanIN/PDAC forma-
tion. Human patients suffering from 
chronic pancreatitis, especially its 
hereditary form, are at increased risk 
for pancreatic cancer (Lowenfels et 
al., 1997), and this mouse model may 
allow us to establish exactly why this 
is the case, and what can be done 
about it. Indeed, although chronic 
inflammatory conditions in numer-
ous tissues are associated with 
increased cancer risk, untangling 
causes, effects, and mechanisms 
has proven very difficult in humans. 
Genetically tractable model systems 
for inflammation-associated cancer 
make it possible to unravel basic 
mechanisms and may also provide a 
preclinical test bed for therapeutics 
targeting the relevant components of 
the inflammatory process.
Here, the authors create a chronic 
pancreatitis-like state by long-term 
treatment with caerulein, an aci-
nar cell secretagogue. Much prior 
research into caerulein-induced 
pancreatitis has focused on two 
important questions: what are the 
molecular mechanisms determin-
ing the severity of injury, and what 
are the cellular mechanisms of 
postinjury repair? With regard to 
the determinants of injury, caeru-
lein treatment induces rapid activa-
tion of the NF-κB transcription fac-
tor; as in other organ inflammation 
models, blocking this activation 
appears to blunt subsequent pan-
creatitis (Gukovsky et al., 1998). 
As expected, Guerra et al. (2007) 
observe NF-κB activation in aci-
nar cells of caerulein-treated mice, 
although this activation occurs to 
the same extent in wild-type and 
KrasG12V-expressing pancreata, and 
little or no NF-κB activation is seen 
in the actual PanIN lesions or tumors 
induced by KrasG12V. Thus, while the 
current results fail to definitively 
characterize the role of NF-κB in 
PDAC initiation and progression, this unique system for the study 
of pancreatitis-associated cancer 
should provide new opportunities to 
resolve this important issue.
The second question regarding 
caerulein-induced pancreatitis is also 
likely to be relevant here: how does 
injured pancreatic tissue repair itself? 
Caerulein-induced pancreatitis is one 
of the experimental insults known to 
provoke expansion of metaplastic 
tubular complexes, and one school 
of thought suggests that metaplastic 
epithelial cells serve as progenitors to 
replace lost acinar tissue (Jensen et 
al., 2005). In in vitro culture systems, 
activation of the Notch and/or EGF 
receptor pathways causes acinar 
cells to dedifferentiate and assume 
a metaplastic phenotype (Miyamoto 
et al., 2003), potentially mimicking 
a process induced by injury in vivo. 
Alternatively, metaplasia may repre-
sent the induced expansion of cen-
troacinar cells (Stanger et al., 2005), 
and it is important to recognize that 
acinar cell dedifferentiation and cen-
troacinar expansion are in no way 
mutually exclusive events (Figure 1). 
Whatever the source, one might imag-
ine that pancreatitis causes other-
wise quiescent adult cells to assume 
a progenitor-like phenotype, in which 
they are more susceptible to transfor-
mation by oncogenic Kras. It should 
be emphasized that this possibility 
is not strictly academic, as it implies 
that interfering with injury-induced 
metaplasia might prevent the earliest 
stages of pancreatic cancer.
This work represents the first direct 
demonstration that cells in adult 
mouse pancreas are susceptible to 
transformation by activated Kras, 
and the first model for pancreatitis-
associated tumor promotion. Further 
work, using Cre lines with stricter 
specificity for duct, centroacinar, or 
acinar cells, will be required to more 
definitively resolve the cell-of-origin 
problem for PDAC, and it may yet 
turn out that the precise cell of origin 
matters less than the context in which 
that cell finds itself—i.e., whether 
Kras mutations occur in the context 
of inflammation and/or regenerative 
metaplasia. Nonetheless, the results 
of Guerra et al. (2007) represent a Cancer Cell major advance in the field of pancre-
atic cancer modeling and provide an 
important foundation for future stud-
ies of pancreatic cancer initiation and 
progression.
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